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A B S T R A C T
This work presents the tuning of drug-loaded scaffolds for bone regeneration as dual-drug delivery
systems. Two therapeutic substances, zoledronic acid (anti-osteoporotic drug) and ibuprofen (anti-
inflammatory drug) were successfully incorporated in a controlled manner into three dimensional
designed porous scaffolds of apatite/agarose composite. A high-performance liquid chromatography
method was optimized to separate and simultaneously quantify the two drugs released from the dual-
drug codelivery system. The multifunctional porous scaffolds fabricated show a very rapid delivery of
anti-inflammatory (interesting to reduce inflammation after implantation), whereas the anti-
osteoporotic drug showed sustained release behaviour (important to promote bone regeneration).
Since ibuprofen release was faster than desired, this drug was encapsulated in chitosan spheres which
were then incorporated into the scaffolds, obtaining a release profile suitable for clinical application. The
results obtained open the possibility to simultaneously incorporate two or more drugs to an osseous
implant in a controlled way improving it for bone healing application.
ã 2015 Published by Elsevier B.V.
7 1. Introduction
8 In recent decades, social development has led to an aging
9 population as well as a considerable increase in the number of
10 traffic accidents. Both factors, as a consequence of the increased life
11 expectancy and the way of life in developed countries, have
12 contributed significantly to an exponential increase in different
13 bone diseases. Consequently, treatment of bone defects continues
14 generating a considerable effort in the scientific community
15 (Arcos et al., 2014; Drosse et al., 2008). In this sense, tissue
16 engineering (TE) (Fisher and Mauck, 2013; Langer and Vacanti,
17 1993) has played a key role as it has introduced new strategies
18 based on the development of composite systems that integrate
19 cells, growth factors, and scaffolds, (Drosse et al., 2008; Eisenbarth,
20 2007; Vallet-Regí and Ruiz-Hernández, 2011) avoiding major
21 drawbacks associated to autografts and allografts (O’Brien, 2011).
22 TE develops substrates that restore, maintain or improve the
23function of damaged tissues (Langer, 2000). In case of damaged
24bone, TE scaffolds with added drug delivery function, have
25emerged as an attractive approach in recent years (Catauro
26et al., 2015a; Mouriño et al., 2013). Q3
27In bone TE, biocompatible, biodegradable and interconnected
28highly porous scaffolds in a three dimensional (3D) geometry are
29desirable. In this sense, composite scaffolds which combine
30biopolymers and bioactive ceramics are being developed for this
31application (Catauro et al., 2015b; Garg and Goyal, 2014; Mallick
32and Cox, 2013; Mouriño et al., 2013). Great attention has been
33focused Q4on hydrogels as biopolymers because of its resemblance to
34the extracellular fluids (Fisher et al., 2014; Malda et al., 2013). They
35have been studied for different medical applications, such as drug
36delivery systems and bionanotechnology (Ankareddi and Brazel,
372007; Gaharwar et al., 2014; Peppas et al., 2006). In particular, the
38natural polysaccharide agarose, which is a thermo sensitive
39hydrogel, has been successfully used in tissue engineering and
40other biological applications (Cheng et al., 2007; Gruber et al.,
412006; Luo and Shoichet, 2004; Marras-Marquez et al., 2014; Rotter
42et al., 1998). Inclusion of hydroxyapatite (the mineral phase
43present in bone) on hydrogels improves both the mechanical
44stability and bioactivity (Juhasz et al., 2010) and also induces an
45osteoinductive and osteoconductive behaviour. In this sense,
46carbonate-substituted hydroxyapatite shows better bioactivity
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47 in vitro and in vivo than stoichiometric hydroxyapatite
48 (Porter et al., 2005). Moreover, nanoscale particulate apatites
49 are being increasingly considered in composite scaffolds to closely
50 mimic the nanosized features of natural bone.
51 Following the implantation of a scaffold, the material is still not
52 vascularized. Therefore, systemic administration of drugs would
53 not be effective at this stage. Drug release from the scaffolds could
54 provide an adequate therapeutic concentration of the drug in the
55 target site. Moreover, the simultaneous release of two or more
56 therapeutic substances with different pharmacological activity
57 may improve the outcome in different pathologies (Aderibigbe
58 et al., 2015; Lee et al., 2008).
59 Most of the fabrication processes to obtain scaffolds with 3D
60 designed porosity employ organic solvents, high temperature or
61 acidic conditions that preclude the incorporation of bioactive
62 molecules and drugs (Fierz et al., 2008; Martínez-Vázquez et al.,
63 2013). In previous work we have described an easy and inexpensive
64 method to obtain agarose/hydroxyapatite scaffolds with hierar-
65 chical porosity at room temperature for bone repair application
66 (Peña et al., 2010; Román et al., 2011). Biocompatibility studies
67 demonstrate that these scaffolds allow the culture of osteoblasts
68 inside and outside the material (Alcaide et al., 2010; Cabañas et al.,
69 2014). Recently, these scaffolds were investigated as protein
70 release matrices with different release kinetics depending on the
71 strategy used to incorporate the protein into the scaffold (Cabañas
72 et al., 2014).
73 This work aims to improve the functionality of these
74 biodegradable scaffolds, turning them into dual-drug delivery
75 systems (DDDS) for bone regeneration. In this sense, we have
76 designed a DDDS for bone regeneration with two drugs widely
77 used in traumatology: zoledronic acid (a bisphosphonate anti-
78 resorptive drug) and ibuprofen (a nonsteroidal anti-inflammatory
79 drug). Bisphosphonates are used in standard clinical practice for
80 the treatment of diseases associated with increased bone
81 resorption, such as osteoporosis, and might enhance bone
82 regeneration when included in scaffolds (Cattalini et al., 2012;
83 Coleman et al., 2011; Giger et al., 2013; Nancollas et al., 2006;
84 Rosenqvist et al., 2014). On the other hand, ibuprofen is commonly
85 prescribed to relieve pain due to inflammation that arises from
86 different osseous pathologies or surgical treatments (Mouriño and
87 Boccaccini, 2010; Rainsford, 2013), and it is also commonly
88 prescribed simultaneously with bisphosphonates in order to
89 minimize one of its main side effects: the “flu-like syndrome”
90 (Coleman et al., 2011). This DDDS should have a long-term release
91 of zoledronic acid (to enhance bone regeneration) and a relatively
92 fast delivery of ibuprofen (to reduce inflammation).
932. Materials and methods
942.1. Materials
95Nanocrystalline hydroxycarbonateapatite (nHCA) was prepared
96by a precipitation method from Ca(NO3)2!4H2O, (NH4)2HPO4 and
97(NH4)2CO3 aqueous solutions at pH 9.2 (NH4OH solution) and 37 "C
98(Padilla et al., 2008).
99Agarose polymer (for routine use) was purchased from
100Sigma–Aldrich, Steinheim, Germany; as well as Chitosan (from
101crab shells, min. 85% deacetylated) and Sodium Tripolyphosphate,
102TPP (Tech., 85%). Zoledronic acid (ZOL) monohydrate and ibuprofen
103(IBU) antinflamatory were kindly provided by Novartis Pharma-
104ceuticals AG (commercial name Zometa) and by Normon
105Laboratories S.A. (Madrid, Spain), respectively.
1062.2. Dual-drug delivery systems preparation and characterization
107Three dimensional interconnected porous agarose/nHCA scaf-
108folds containing drugs were fabricated using a shaping process
109patented by the authors: GELPOR3D (Peña et al., 2010; Vallet-Regí
110et al., 2010). The scaffolds were loaded with two drugs in two
111different steps (during the scaffold fabrication and after its
112consolidation). Briefly, the fabrication method consists of the
113following steps (Fig. 1): the agarose powder was suspended in
114deionized water (3.5% w/v) and heated to 90 "C with continuous
115stirring; once a translucent sol was achieved, temperature was
116gradually decreased to 45 "C and then the ceramic powder (nHCA)
117was added. In this step, one of the drugs (ZOL or IBU alternatively)
118was added as powder to the suspension (drug 1), which was
119incorporated through the whole volume of the material. The slurry
120so obtained was poured into a designed mold (a cube constituted
121by rigid filaments of stainless steel 1 mm in diameter arranged
122parallel to each other). After five minutes at room temperature,
123complete consolidation of the bodies was reached. After with-
124drawal of the designed mold, the scaffolds, freshly prepared, were
125easily cut and shaped (Fig. 1). Then, the pieces were freeze-dried
126(Heto Drywinner, freezing temperature and sublimation pressure
127of #86 "C and 0.05 mbar, respectively).
128Once the scaffolds containing drug 1 were dried, the same
129amount of another drug (drug 2, IBU or ZOL alternatively) was
130incorporated into the scaffolds by injection of an aqueous solution,
131exploiting its hydrogel-like behaviour (Fig. 1). Afterwards, the
132systems were freeze-dried again.
133The composition employed to prepare the DDDS (50% ceramic
134and 50% hydrogel) was chosen according to previous results
Fig. 1. Fabrication method of dual-drug delivery systems.
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135 (Román et al., 2011): compositions with low contents of agarose
136 result in an insufficient ceramic particle-polysaccharide binder
137 interaction that may cause the particles migration once implanted.
138 On the other side, slurries containing high ceramic loads may
139 result too viscous to be poured in the mould and fill the interstices
140 between the rigid filaments.
141 Thus, two types of systems containing 45% nHCA, 45% agarose
142 and 10% drugs (5% IBU + 5% ZOL) (data are expressed in weight %)
143 were fabricated: AH-zol-ibu sample (where zoledronic acid was
144 incorporated during the scaffold preparation, and the ibuprofen
145 was added after scaffold consolidation) and AH-ibu-zol sample (in
146 which ibuprofen was added before consolidation and the
147 zoledronic acid was incorporated after) (Fig. 1).
148 The fabricated DDDS were characterised by X-ray diffraction
149 (XRD) with a Philips X-Pert MPD diffractometer, scanning electron
150 microscopy (SEM) in a JEOL 6400 and Hg intrusion porosimetry
151 using a Micromeritics AutoPore III 9410 porosimeter. Fourier
152 Transform Infrared (FTIR) spectra were obtained in a Nicolet Nexus
153 spectrometer equipped with a Smart Golden Gate Attenuated Total
154 Reflectance (ATR) accessory.
155 2.3. Chitosan spheres preparation and characterization
156 Ibuprofen-loaded chitosan spheres were prepared by the
157 following procedure(Agnihotri et al., 2004): ibuprofen (150 mg)
158 was dispersed in 10 mL of 1.5% chitosan solution in 0.5% acetic acid
159 in deionized water. This suspension was added drop wise to a 10%
160 Sodium Tripolyphosphate (TPP) solution in deionized water under
161 gentle stirring. Chitosan spheres formed almost immediately and
162 were cured for 20 min. Then they were filtered and dried in an oven
163 at 37 !C overnight (sample CT-ibu).
164 The spheres containing IBU were then introduced in the
165 composite scaffolds following the same procedure previously
166 described to introduce drug 1 (sample AH-CT-ibu).
167 The systems were characterised by scanning electron micros-
168 copy (SEM) in a JEOL 6400, Fourier Transform Infrared (FTIR)
169 spectra were obtained in a Nicolet Nexus spectrometer equipped
170 with a Smart Golden Gate ATR accessory.
171 2.4. In vitro drugs release study
172 In vitro delivery assays were performed by soaking scaffolds of
173 1 cm side in 10 mL saline solution (NaCl 0.9%) at 37 !C. The pH of the
174 release medium was adjusted to 7.4 (physiological pH) with Tris-
175 Buffer. To avoid limitation of the delivering rate by external
176 diffusion constrains, continuous stirring was maintained during
177 the delivery assays. The volume of release medium employed was
178 chosen to ensure sink conditions: The concentration of the drugs in
179 the medium was never higher than 20% of their solubility in that
180 medium. Aliquots of 150 mL were extracted at different times.
181 The concentration of released drugs from the loaded scaffolds
182 was monitored by reverse-phase high-performance liquid chro-
183 matography (RP-HPLC) in a Waters Alliance automatic analysis
184 system with a Model #2695 separations module coupled to a
185 Model #2996 photo-diode array detector. Chromatographic
186 separations were carried out with a 250 " 4.6 mm prepacked
187 analytical column Mediterranea Sea18 (Teknokroma Inc.) contain-
188 ing 5 mm C-18 functionalized silica beads.
189 In order to separate and quantify the drugs introduced into the
190 scaffolds, specific analytical conditions were developed and the
191 following method was employed. The gradient mobile phase was a
192 mixture of aqueous phosphate buffer 10 mM at pH 3 and methanol
193 (Vallet-Regí et al.,1998; Vila et al., 2013). The best resolution of two
194 drugs was achieved with the following mobile composition: the
195 initial mixture composition was 90:10 (v/v) for the first 5 min, and
196 then was changed to 15:85 (v/v) over a period of 10 min, keeping
197the flow with the mobile phase for other 25 min. The flow rate of
198the mobile phase was 0.7 mL min#1 and the injection volume was
19910 mL. The column temperature was maintained at 37 !C.
200The detection of the released drug was performed by UV at
201different wavelengths: 210 nm for ZOL and 219 nm for IBU.
202Chromatograms were recorded using Millenium Software. Under
203these conditions, the retention time of the ZOL was 4 $ 0.5 min,
204whereas the IBU retention time was 25 $ 0.6 min (Fig. 2). Several
205solutions at concentrations ranging from 0.003 to 0.5 mg mL#1
206(ZOL) or 0.003 to 0.125 mg mL#1 (IBU) in aqueous NaCl 0.9%
207buffered at pH 7.4 were used as standards. In addition, the
208chromatographic peaks were stable appearing at the same
209retention time during the analysis and no degradation peaks were
210present in the chromatograms. Results were processed with the
211software OriginPro8 (OriginLab Northampton, MA)
2123. Results and discussion
213Multifunctional 3D scaffolds based on nano-hydroxycarbona-
214teapatite/agarose composites have been fabricated at room
215temperature through a shaping method Q5named GELPOR3D
216(Peña et al., 2010; Román et al., 2011; Vallet-Regí et al., 2010).
217These scaffolds were loaded with two drugs, (ZOL and IBU), in two
218different steps. In these systems, the drug included during scaffold
219fabrication, drug 1, is mentioned first and the drug included after
220scaffold consolidation, drug 2, is stated last, giving two different
221materials: AH-zol-ibu and AH-ibu-zol.
222The method used to obtain these DDDS allows a complete
223control over the amount of drugs present in the scaffolds. This
224constitutes a significant advantage versus other designed porosity
225systems that depend on immersing the scaffolds in highly
226concentrated solutions of the drugs to load them into the material
227(a very inefficient process).
228The addition of the drugs (10 wt.%) during the scaffold
229fabrication does not affect the body consolidation process neither
230the textural features of the scaffolds as demonstrated by SEM and
231Hg porosimetry studies. These DDDS show a macroporous
232structure constituted by a designed 3D network of interconnected
233pores of around 900 mm, and a connected porosity due to freeze-
234drying with diameters between 100 and 200 mm (Fig. 3). Scaffolds
235fabricated with similar composition and drying method to those
236used in this work (Román et al., 2011) showed a porosity around
23795%, with 30% for the pores with the highest diameter, around 65%
Fig. 2. Typical HPLC chromatogram of ZOL and IBU standard mixture at 219 nm.
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238 for the 100–200 mm pores and less than 3% for pores around
239 50–100 nm (due to the structure resulting from the coating of
240 nHCA particles by the agarose).
241 The presence of loaded drugs into the scaffolds was confirmed
242 by FTIR spectra. Fig. 4 shows FTIR spectrum corresponding to AH-
243 ibu-zol scaffold. (The FTIR spectrum corresponding to AH-zol-ibu
244 was very similar and it is not included in the figure for the sake of
245 clarity). The spectra corresponding to IBU, ZOL and the scaffold
246 without any loaded drug (AH) or containing just zoledronic acid
247 (AH-zol) are also included for comparative purposes.
248 FTIR spectrum of AH-ibu-zol shows the presence of character-
249 istic bands associated to functional groups corresponding to nHCA
250 and agarose (see FTIR spectrum of sample AH) and additional
251 bands due to the drugs were also detected. The most intense band
252 of ibuprofen, at 1720 cm!1, that corresponds to carboxylic acid
253 group, -COOH, (Szegedi et al., 2012) is not observed. However, a
254 new band at 1545 cm!1, corresponding to carboxylate ion COO!,
255 can be appreciated in the co-loaded scaffold. This indicates the
256 deprotonation of the acid group of IBU during the synthesis
257 process, due to the basic environment provided by the nHCA, as it
258 has been observed in other basic materials (Krupa et al., 2010). This
259 deprotonation was not observed in scaffolds prepared without
260 nHCA (Supporting Information). On the other hand, the bands
261 corresponding to the aromatic ring chains of zoledronic acid
262 (Pascaud et al., 2012), ca. 1548 and 1578 cm!1, can be observed in
263 the fabricated scaffolds with ZOL, indicating that aromatic rings
264 remain unmodified. Moreover, the vibration bands of ZOL at
265 1300 and 1321 cm!1 attributed to P—O bond (Waghe et al., 2006)
266 are shifted to 1286 and 1307 cm!1, respectively, in the spectra
267 corresponding to scaffolds containing ZOL (AH-zol and AH-ibu-zol
268 scaffold). This displacement can be attributed to the interaction
269 between the ZOL and the nHCA, as the bisphosphonates possess a
270 pyrophosphate-like chemical structure that confers a strong
271 affinity of calcium by a chelate formation (Bujoli et al., 2006;
272 Juillard et al., 2010; Vargas-Becerril et al., 2013).
273 Systems containing ZOL (forming a chelate with Ca from the
274 ceramic component) and/or IBU (with its carboxylic group
275 deprotonated) were immersed in aqueous solution to study the
276 co-release of the drugs. To quantify zoledronic acid and ibuprofen,
277 a RP-HPLC method was developed in order to determine the
278 concentration of both drugs (since they are being released
279 simultaneously, and their UV–vis spectra overlap). Firstly, the
280 specific analytical conditions were studied to separate both drugs
281by optimizing the composition of the mobile phase (Fig. 2):
282methanol and aqueous phosphate buffer in various ratios. After
283separation they were quantified by UV at different wavelengths:
284210 nm for ZOL and 219 nm for IBU. An important concern
285regarding drug release from scaffolds is to ensure the drug
286stability during its incorporation and release. Drug stability in this
287study was assured by the unmodified UV/vis spectra of both drugs
288throughout the analysis time. Again, this proves the versatility of
289the scaffold preparation procedure, based on the gelation of
290agarose, carried out at mild conditions, allowing the incorporation
291of active molecules during the process without modifying them.
292Similar systems rely on the setting reaction of cements, an
293exothermic process that can actually reduce the activity of the
294incorporated drugs (Vorndran et al., 2010).
295Fig. 5 shows the release profiles of IBU and ZOL as a function of
296the incorporation method of the drug at pH 7.4. Data depicted in
297this figure show that ibuprofen has a short-term release while
298zoledronic acid has a long term and sustained release behaviour.
299Moreover, independent release behaviours of the drugs were
300observed, since the presence of a drug does not influence the
301release of the other (single drug systems have also been studied as
302reference, data not shown).
Fig. 3. AH-zol-ibu scaffold: photograph (a); SEM micrographs at different
magnifications (b,c); schematic representation of the dual matrix (d).
Fig. 4. FTIR spectra corresponding to (from top to bottom): AH scaffold; AH-ibu-zol
scaffold; AH-zol scaffold; zoledronic acid and ibuprofen.
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303 In a physiological pH saline solution, IBU is practically released
304 in 3 h, for both types of incorporation, whereas for this time, just
305 around a 3% of ZOL is released when it is added during the scaffold
306 fabrication (AH-zol-ibu) and 9% when it was incorporated after
307 fabrication (AH-ibu-zol). Data collected in this figure show that, at
308 72 h, only 20% (AH-ibu-zol) or 10% (AH-zol-ibu) of zoledronic acid
309 has been released.
310 Contrarily to what one would expect, both loading modes
311 (during and after scaffold manufacture) resulted in rather similar
312 in vitro release profile of ibuprofen: a very fast release of the drug,
313 related to the rapid swelling of the scaffolds in aqueous solution
314 observed in previous studies. (Cabañas et al., 2014) On the other
315 hand, the retention of antiosteoporotic drug is related to the
316 complexation between the phosphonate groups of zoledronic acid
317 and the Ca ions of nHCA, previously mentioned. This bonding
318 nHCA-ZOL has been found to yield protection against the observed
319 cytotoxic effects of ZOL in vitro. (Murphy et al., 2014) The lower
320 release observed for AH-zol-ibu indicates that the complexation
321 reaction is facilitated when ZOL is introduced during the
322 fabrication process.
323 Even though these results match the initial objective of this
324 work (a very slow release of zoledronic acid and a very fast release
325 of ibuprofen), ibuprofen release is too fast for the clinical
326 application we are aiming at. The drug should be released during
327 a short period of time (a few days) in order to yield a relevant anti-
328 inflammatory effect. However, ibuprofen release should not last
329 much longer, since prolonged anti-inflammatory treatment might
330 difficult the regeneration process and, therefore, deteriorate the
331 clinical outcome (Thomas and Puleo, 2011).
332 In order to extend ibuprofen release, and because of the
333 versatility of the scaffold fabrication process, the drug was
334 encapsulated in chitosan-TPP spheres (CT) (648.016 ! 22.03 mm
335 in diameter) before being introduced in the scaffold. Chitosan is a
336 biodegradable natural polysaccharide widely used in drug delivery
337 systems (Agnihotri et al., 2004). Drug-loaded chitosan spheres,
338 containing a 26 wt.% of IBU (CT-ibu) were introduced in the slurry
339 before its addition to the 3D-mold. These CT-ibu spheres isolated,
340 or included in the composite scaffolds (AH-CT-ibu) together with a
341 schematic representation of the system are shown in Fig. 6. FTIR
342 spectrum of CT-ibu spheres shows that IBU is present with its
343 carboxylic group protonated (Supporting information).
344 Ibuprofen release studies from spheres isolated (CT-ibu) and
345 scaffolds with spheres within them (AH-CT-ibu) were carried out
346in the same conditions as those used previously. The results are
347shown in Fig. 7. We can see a slower release from the sphere-
348loaded scaffolds than from the isolated chitosan spheres (and, in
349both cases, slower than non-encapsulated ibuprofen-loaded
350scaffolds). In the case of the scaffold with encapsulated ibuprofen,
351with minimised burst effect, its release lasts more than 2 days,
352what would be suitable for bone healing.
353The release profiles of Figs. 5 and 7 were fitted to different
354kinetic models, in order to try to determine the mechanism driving
355drug release (Costa and Sousa Lobo, 2001). Table 1 summarizes the
356kinetic parameters resulting from the better fittings of zoledronic
357acid and ibuprofen release.
358For the release of zoledronic acid, the best fit was Q6obtained by
359the power law equation known as Korsmeyer–Peppas equation
360(Peppas, 2000) (Eq. (1)):
Mt
M
¼ ktn (1)
361362where Mt/M is the accumulative amounts of drug release at time t;
363k is a kinetic constant and n is an exponent which characterised the
364mechanism of drug release and it ranges between n = 0.5
Fig. 5. Release profiles of ZOL (5) and IBU (*) from the DDDS: AH-zol-ibu (—) and
AH-ibu-zol (- - - -) at pH 7.4.
Fig. 6. Photograph and SEM micrograph of CT-ibu spheres (a, b); SEM micrograph of
AH-CT-ibu scaffold with arrows pointing CT-ibu spheres (c); schematic represen-
tation of the new dual matrix (d).
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Fig. 7. Release profiles of IBU from non-encapsulated IBU-loaded scaffolds (AH-
ibu), IBU-loaded chitosan spheres (CT-ibu) and composite scaffolds containing
drug-loaded spheres (AH-CT-ibu) at pH 7.4.
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365 (for Fickian diffusion), and n = 1 (for Case II transport), respectively,
366 being the inter-mediate values indicative of anomalous transport.
367 In our case the value of the exponent n obtained was lower (ca.
368 0.2). This low value may be attributed to a non-typical Fickian
369 diffusion mechanism with some physico-chemical interference
370 (Chen and Zhu 2012; Tamimi et al., 2008). These data agree with
371 the nHCA and ZOL interaction described above, the formation of a
372 chelate and detected by FTIR spectra. Comparing the kinetic fitting
373 for ZOL release, a higher value of k when ZOL is introduced after the
374 scaffold consolidation can be observed, what is in agreement with
375 the higher amount of the drug released from this scaffold.
376 On the other hand, the release of non-encapsulated ibuprofen
377 from the scaffolds showed in Fig. 5 follows a first order exponential
378 decay model (according to the Noyes–Whitney equation)
379 (Peppas, 2000) (Eq. (2)):
Mt
M
¼ Að1 # e#KtÞ (2)
380381 with A = (Mt/M)max being the maximum number of biomolecules
382 released. The release rate constant, K, gives information about the
383 solvent accessibility and the diffusion coefficient through the
384 scaffold channels. In this case, no appreciable difference is
385 observed in the kinetic fitting of IBU release introduced before
386 or after scaffold consolidation (Table 1). To determine the
387 mechanism underlying ibuprofen release, a scaffold AH-ibu was
388 immersed in saline solution at pH 6.5, and the release profile of the
389 drug was analyzed (Supporting information). IBU release at pH
390 6.5 was slower than at pH 7.4, as can be observed in the release
391 profile and in the kinetic fitting to Eq. (2) (A = 94 % 4%, K = 0.0044
392 h#1%0.0005, R2 = 0.987). Given that solubility of IBU is lower at
393 acidic pH, and that the dissolution rate is a function of the
394 solubility of a molecule (Costa and Sousa Lobo, 2001), the change in
395 the release profile of IBU between the two cases (at pH 7.4 and pH
396 6.5) might indicate that the mechanism driving non-encapsulated
397 ibuprofen release from this scaffolds is merely the dissolution of
398 the drug.
399 The slower ibuprofen release from chitosan spheres (inside a
400 scaffold or isolated) can be described using, again, the Korsmeyer–
401 Peppas equation (Table 1). In both cases, the n value is close to 0.5;
402 this implies that the mechanism behind drug release is diffusion
403 through the walls of the chitosan spheres. Even though in both
404 cases, the same kinetic model can be used, the kinetic constant (k)
405 is higher in the isolated spheres, what agrees with the faster
406 release observed in that case, since in the spheres embedded inside
407 a scaffold, ibuprofen has to get out of the scaffold once it has
408 diffused out of the chitosan spheres.
409 According to the drug release data, the proposed strategy with
410 the dual pharmacological effect could be a versatile option for the
411 treatment of bone injuries that would require bone replacement.
412 The apatite/agarose scaffold itself could allow bone regeneration,
413 since previous in vitro studies (Cabañas et al., 2014) showed that
414the material stimulated osteoblast proliferation and the cells
415colonized the interconnected macroporous scaffolds. At the same
416time, the drugs included in it would provide an environment
417where bone regeneration would be enhanced (by the slow release
418of ZOL) and the inflammation in the area would be reduced in the
419short-term (by the fast release of IBU).
4204. Conclusions
421Multifunctional 3D designed porous scaffolds for bone regen-
422eration were fabricated by a simple conformation method carried
423out in mild conditions that allow introducing many different
424biomolecules avoiding their degradation during scaffold manufac-
425ture. Two biological active substances, zoledronic acid (an
426antiresorptive drug) and ibuprofen (an antiinflammatory drug),
427have been incorporated into the scaffolds and were co-delivered to
428the medium following different tuneable release profiles. The
429composition of the scaffolds allows the bisphosphonate to be
430retained by the ceramic, nHCA, and the inclusion of ibuprofen-
431loaded chitosan spheres enables the adjustment of its release
432behaviour.
433The development of a liquid chromatographic method allowed
434the separation and simultaneous quantification of both drugs
435which are released following different mechanisms, which can be
436described employing several kinetic models.
437The results obtained show the potential of these agarose/
438nanohydroxycarbonateapatite scaffolds to retain and slowly
439release zoledronic acid, as well as to quickly deliver ibruprofen
440to the surrounding tissue. Although these DDDS have been studied
441for simultaneous delivery of drugs with antiinflamatory and
442antiosteoporotic properties, this approach allows the development
443of multifunctional scaffolds to deliver multiple pharmaceutical or
444biological agents for bone tissue regeneration.
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Table 1
Kinetic parameters Q9of zoledronic acid (ZOL) and ibuprofen (IBU) released from different materials.
Drug Material Model Kinetic parameters Fit parameters
ZOL AH-ibu-zol Korsmeyer–Peppas k = 2.5 (h#n) % 0.2 R2 = 0.993
Mt/M = ktn n = 0.24 % 0.01
AH-zol-ibu Korsmeyer–Peppas k = 1.03 (h#n) % 0.04 R2 = 0.997
Mt/M = ktn n = 0.206 % 0.005
Non-encapsulated IBU AH-ibu-zol First order release A = 96.1 % 1 R2 = 0.991
Mt/M = A(1 # e#Kt) K = 0.056 h#1% 0.004
AH-zol-ibu First order release A = 97.23 % 2 R2 = 0.992
Mt/M = A(1 # e#Kt) K = 0.051 h#1% 0.004
Encapsulated-IBU CT-ibu Korsmeyer–Peppas k = 9.69 (h#n) % 2.85 R2 = 0.987
Mt/M = ktn n = 0.43 % 0.06
AH-CT-ibu Korsmeyer–Peppas k = 1.28 (h#n) % 0.215 R2 = 0.992
Mt/M = ktn n = 0.525 % 0.023
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